A prospective analysis of hormone replacement therapy (HRT) after oophorectomy and breast cancer risk in BRCA1 mutation carriers (n = 872; 92 incident cancers, and 7.6 years mean follow-up), we recently reported no relationship with the use of any type of HRT (HR = 0.97; 95% CI 0.62–1.52); however, there were differing effects by formulation type [33]. This evidence concerns the gene BRCA1 and breast carcinoma.